Piboserod

Piboserod is a selective 5-HT4 receptor antagonist which was marketed and manufactured by Novartis for the management of irritable bowel syndrome and other gastrointestinal disorders. However, it was withdrawn from the market due to concerns about serious cardiovascular side effects.

Etymology

The term "Piboserod" is a coined name, with no specific etymology. It is a synthetic compound and its name is derived from its chemical structure.

Pharmacology

Piboserod works by blocking the action of the neurotransmitter serotonin at the 5-HT4 receptor. Serotonin is a chemical that is involved in the regulation of the gut's motility and sensitivity. By blocking the action of serotonin, Piboserod can help to regulate the movement of the gut and reduce the symptoms of irritable bowel syndrome.

Clinical Use

Piboserod was used for the treatment of irritable bowel syndrome (IBS) in women who have constipation as their main symptom. It was also used for the treatment of chronic constipation in men and women under certain circumstances.

Side Effects

The use of Piboserod has been associated with a number of side effects. The most common side effects include headache, abdominal pain, and diarrhea. However, the drug was withdrawn from the market due to concerns about serious cardiovascular side effects, including heart attacks and strokes.

Withdrawal from Market

In 2007, Novartis withdrew Piboserod from the market after a review of clinical trial data showed an increased risk of serious cardiovascular side effects. The decision to withdraw the drug was made in consultation with regulatory authorities.

See Also

• 5-HT4 receptor
• Irritable bowel syndrome
• Novartis
• Serotonin

Piboserod Resources
Latest articles Most recent articles Ongoing trials	Wikipedia